A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Obesity, Diabetes Mellitus, Type 2

In brief

This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-ALK7 in adult participants with obesity without Type 2 Diabetes Mellitus (T2DM) (Part 1), and the safety, tolerability, and PD of multiple doses of ARO-ALK7 in adult participants with obesity with and without T2DM, either as monotherapy or in combination with tirzepatide (Part 2).

Key facts

Study ID

NCT06937203

Run by

Arrowhead Pharmaceuticals

People needed

150

Starts

2025-05-09

Expected to finish

2027-02-01

Last updated by the study team

2026-07-08

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Obesity, defined as body mass index (BMI) between 30-50 kilograms (kg)/square meter (m\^2), inclusive, with weight at Screening not to exceed 159 kg (350 pounds [lbs])
• At least one self-reported, unsuccessful attempt at weight loss with lifestyle modification
• No abnormal finding of clinical relevance at Screening that could adversely impact participant safety during the study or adversely impact study results
• Female participants of childbearing potential must agree to use highly effective contraception and male participants with female partners of childbearing potential must agree to use a condom during the study and for at least 90 days following the end of the study or last dose of study drug, whichever is later. Participants must not donate sperm or eggs during the study for at least 90 days following the end of the study or last dose of study drug, whichever is later

You may not qualify if…

• Self-reported (or documented) weight gain or loss >5% within 3 months prior to Screening
• Use of glucagon-like peptide-1 receptor agonist (GLP-1RAs) (liraglutide, semaglutide, etc.) for any indication within 6 months prior to Screening
• Use of non-GLP-1R medications for weight loss within 3 months prior to Screening, including but not limited to naltrexone/bupropion, orlistat, phentermine/topiramate, and other prescription or over-the-counter medication or supplement taken for weight loss purposes
• Obesity attributable primarily in the Investigator's opinion to medication use, monogenic or endocrinologic disorders (other than polycystic ovary syndrome)
• History of prior surgical or device-based therapy for obesity (including endoscopic bariatric procedures)
• Use of medications or therapies strongly associated with weight gain, alterations in body composition, or increase in muscle mass, within 3 months prior to Screening
• Type 1 diabetes mellitus
• Note: Additional inclusion/exclusion criteria may apply per protocol.

Where it is running

• Research Site 4 — Rotorua, New Zealand (enrolling)
• Research Site 8 — Morayfield, QLC, Australia (enrolling)
• Research Site 5 — Grafton, Auckland, New Zealand (enrolling)
• Research Site 6 — Papatoetoe, Auckland, New Zealand (enrolling)
• Research Site 3 — Takapuna, Auckland, New Zealand (enrolling)
• Research Site 1 — Auckland, New Zealand (enrolling)
• Research Site 2 — Christchurch, New Zealand (enrolling)
• Research Site 7 — Nedlands, Western Australia, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.